Literature DB >> 19062062

Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy.

Angela Marzocchetti1, Marco Lima, Troy Tompkins, Daniel G Kavanagh, Rajesh T Gandhi, David W O'Neill, Nina Bhardwaj, Igor J Koralnik.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by JC virus (JCV) for which there is no cure. PML patients who have JCV-specific CD8(+) cytotoxic T lymphocytes (CTL) in their blood have a better clinical outcome. We compared JCV-specific CTL responses in vitro elicited either by JCV peptide-loaded dendritic cells (DC) or by direct peptide stimulation of lymphocytes from 20 HLA-A0201(+) healthy controls, HIV(+) and PML patients. JCV peptide-loaded DC elicited a stronger CTL expansion in 13/15 responders. DC can induce a potent JCV-specific CTL response in vitro, and may constitute a promising approach for PML immunotherapy.

Entities:  

Mesh:

Year:  2008        PMID: 19062062      PMCID: PMC2692892          DOI: 10.1016/j.virol.2008.10.046

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  30 in total

Review 1.  Active immunization of humans with dendritic cells.

Authors:  M V Dhodapkar; N Bhardwaj
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

2.  JC virus induces a vigorous CD8+ cytotoxic T cell response in multiple sclerosis patients.

Authors:  Renaud A Du Pasquier; Marion C Stein; Marco A Lima; Xin Dang; Jims Jean-Jacques; Yue Zheng; Norman L Letvin; Igor J Koralnik
Journal:  J Neuroimmunol       Date:  2006-06-05       Impact factor: 3.478

Review 3.  Recent advances in dendritic cell biology.

Authors:  Sylvia Adams; David W O'Neill; Nina Bhardwaj
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

4.  Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells.

Authors:  Christian Wüthrich; Santosh Kesari; Woong-Ki Kim; Kenneth Williams; Rebecca Gelman; Derek Elmeric; Umberto De Girolami; Jeffrey T Joseph; Tessa Hedley-Whyte; Igor J Koralnik
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

Review 5.  Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?

Authors:  Igor J Koralnik
Journal:  Ann Neurol       Date:  2006-08       Impact factor: 10.422

6.  Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy.

Authors:  Marco A Lima; Angela Marzocchetti; Patrick Autissier; Troy Tompkins; Yiping Chen; Jennifer Gordon; David B Clifford; Rajesh T Gandhi; Nagagopal Venna; Joseph R Berger; Igor J Koralnik
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

7.  Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.

Authors:  M V Dhodapkar; J W Young; P B Chapman; W I Cox; J F Fonteneau; S Amigorena; A N Houghton; R M Steinman; N Bhardwaj
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

8.  Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies.

Authors:  Renaud A Du Pasquier; Patrick Autissier; Yue Zheng; Jims Jean-Jacques; Igor J Koralnik
Journal:  AIDS       Date:  2005-12-02       Impact factor: 4.177

9.  Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors.

Authors:  Elsa F Velazquez; Achim A Jungbluth; Molly Yancovitz; Sacha Gnjatic; Sylvia Adams; David O'Neill; Kira Zavilevich; Tatyana Albukh; Paul Christos; Madhu Mazumdar; Anna Pavlick; David Polsky; Richard Shapiro; Russell Berman; Joanna Spira; Klaus Busam; Iman Osman; Nina Bhardwaj
Journal:  Cancer Immun       Date:  2007-07-12

Review 10.  Adoptive T cell therapy for cancer in the clinic.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

View more
  15 in total

Review 1.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

Review 2.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

Review 3.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

4.  Monoclonal antibodies and progressive multifocal leukoencephalopathy.

Authors:  Joseph R Berger; Sidney A Houff; Eugene O Major
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

Review 5.  Sorting out the risks in progressive multifocal leukoencephalopathy.

Authors:  Leonard H Calabrese; Eamonn Molloy; Joseph Berger
Journal:  Nat Rev Rheumatol       Date:  2014-10-14       Impact factor: 20.543

Review 6.  Update on progressive multifocal leukoencephalopathy.

Authors:  Israel Steiner; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

7.  Polyomavirus JC urinary shedding in kidney and liver transplant recipients associated with reduced creatinine clearance.

Authors:  Shimon Kusne; Regis A Vilchez; Preeti Zanwar; Jorge Quiroz; Marek J Mazur; Raymond L Heilman; David Mulligan; Janet S Butel
Journal:  J Infect Dis       Date:  2012-07-16       Impact factor: 5.226

Review 8.  Progressive multifocal leukoencephalopathy and other forms of JC virus disease.

Authors:  Bruce J Brew; Nicholas W S Davies; Paola Cinque; David B Clifford; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2010-12       Impact factor: 42.937

9.  Determinants of survival in progressive multifocal leukoencephalopathy.

Authors:  A Marzocchetti; T Tompkins; D B Clifford; R T Gandhi; S Kesari; J R Berger; D M Simpson; M Prosperi; A De Luca; I J Koralnik
Journal:  Neurology       Date:  2009-11-10       Impact factor: 9.910

Review 10.  Immune surveillance and response to JC virus infection and PML.

Authors:  Sarah Beltrami; Jennifer Gordon
Journal:  J Neurovirol       Date:  2013-12-03       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.